Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vitamin B6 plus 20AA Compound Amino Acid injection in amyotrophic lateral sclerosis
ChiCTR2300075878Phase 4Recruiting
- Sponsor
- Changzhou Wujin People's Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyridoxine and compound amino acid (20AA) in amyotrophic lateral sclerosis (ALS), sponsored by Changzhou Wujin People's Hospital. Primary endpoint: Overall survival. Started Sep 2023; status: recruiting.
02
Drugs
pyridoxinecompound amino acid (20AA)
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2300075878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075878.